UK’s NICE Says Bristol-Myers Squibb Company’s Orencia Not Recommended for Rheumatoid Arthritis

LONDON (Thomson Financial) - The UK's healthcare spending watchdog NICE has announced that it does not recommend Bristol-Myers Squibb Co's abatacept-based Orencia as a treatment option for people with rheumatoid arthritis, its indicated use.